OVARIAN CANCER METASTATIC RECURRENT
Clinical trials for OVARIAN CANCER METASTATIC RECURRENT explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CANCER METASTATIC RECURRENT trials appear
Sign up with your email to follow new studies for OVARIAN CANCER METASTATIC RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for aggressive ovarian cancer: targeted drug combo enters trial
Disease control Recruiting nowThis study tests a new drug combination for people with a specific, high-risk type of ovarian cancer that has not yet been treated. The treatment includes a targeted drug (disitamab vedotin) plus standard chemotherapy and a blood-vessel blocker (bevacizumab). After initial treatm…
Matched conditions: OVARIAN CANCER METASTATIC RECURRENT
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated May 17, 2026 02:43 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, such as certain ovarian, endometrial, and lung cancers. The drug is designed to target and attack cancer cells that have a specific marker (PTK7). The main goals are to find the safest do…
Matched conditions: OVARIAN CANCER METASTATIC RECURRENT
Phase: PHASE1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 02:40 UTC
-
New hope for ovarian cancer patients resistant to current treatments
Disease control Recruiting nowThis study tests a drug called trastuzumab deruxtecan (T-DXd) in people with ovarian cancer that has come back after treatment with PARP inhibitors. The drug targets a protein called HER2 found on some cancer cells. About 116 adults with HER2-positive ovarian cancer will be rando…
Matched conditions: OVARIAN CANCER METASTATIC RECURRENT
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated May 15, 2026 11:55 UTC